SCHEMBL26928482

SCHEMBL26928482

O=c1[nH]ccc2cc(NCC3CC3)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 11/20 0.48
ROCK2 O75116 7/20 0.48
PRKCD Q05655 2/20 0.45
PRKACA P17612 1/20 0.45
PRKG1 Q13976 1/20 0.45
PKN1 Q16512 1/20 0.45
PKN2 Q16513 1/20 0.45
AAK1 Q2M2I8 1/20 0.45
CDC42BPA Q5VT25 1/20 0.45
Q6ZSR9 Q6ZSR9 1/20 0.45
BMP2K Q9NSY1 1/20 0.45
CDC42BPB Q9Y5S2 1/20 0.45
MAP2K1 Q02750 1/20 0.44
JAK1 P23458 2/20 0.43
JAK2 O60674 1/20 0.42
PRKX P51817 1/20 0.41
PRKCE Q02156 1/20 0.41
PRKD1 Q15139 1/20 0.41
CYP1A2 P05177 1/20 0.41
GRM4 Q14833 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3316750 0.85 MAP2K1 (0.62) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL3313477 0.83 MAP2K1 (0.46) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL17539396 0.79 VCP (0.47) JAK1
SCHEMBL25834155 0.78 KIT (0.52) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL3317132 0.76 ROCK1 (0.42) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL1571595 0.76 ROCK1 (0.47) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL1571597 0.76 ROCK1 (0.47) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL4001968 0.76 ROCK2 (0.56) ROCK1ROCK2PKN2MAP2K1CYP1A2
SCHEMBL1572362 0.74 KIT (0.49) ROCK1ROCK2PRKCDPRKACAPRKG1
SCHEMBL1572360 0.74 KIT (0.49) ROCK1ROCK2PRKCDPRKACAPRKG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4536356-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS Xenon Pharmaceuticals Inc. (CA) 2025-04-16 EP disclosed
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 US disclosed
WO-2023239729-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2023-12-14 WO disclosed
WO-2023239729-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2023-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNA1, KCNB1, KCNB2 ROCK1 2215/4885ROCK2 3095/4885PRKCD 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.